Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat effects on right ventricular size and function in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
2023-509696-17-00Phase 4Completed
- Sponsor
- Thoraxklinik am Universitätsklinikum Heidelberg
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Thoraxklinik am Universitätsklinikum Heidelberg. Primary endpoint: Change in right ventricular and right atrial area. Started Aug 2024; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2023-509696-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509696-17-00.